FDA approves controversial new Alzheimer’s drug
April 12, 2023
Source: drugdu
163
On April 4th, 2023, Pharmaceutical Technology reported that the FDA has approved a new treatment for Alzheimer's disease called Aduhelm. The drug, developed by Biogen, is the first new Alzheimer's treatment to be approved in nearly two decades. However, the approval has been controversial, with some experts questioning the drug's efficacy and high cost.
Aduhelm targets a protein called beta-amyloid, which is believed to play a role in the development of Alzheimer's disease. The drug has been shown to reduce the buildup of beta-amyloid in the brain, but some experts have raised concerns about the drug's efficacy and potential side effects.
The drug is also very expensive, with an estimated cost of $56,000 per year per patient. This has led some experts to question whether the drug is worth the cost.
Despite the controversy, the approval of Aduhelm is seen as a significant development in the fight against Alzheimer's disease, which affects an estimated 6 million people in the US.
Reference:
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions November 22, 2024
- Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan November 22, 2024
- Junshi Biotechnology introduces two cancer dual target fusion protein drugs November 22, 2024
- China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical November 22, 2024
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
